Open Access
Volume 7, Number 1, March 2017
Article Number 1
Number of page(s) 8
Published online 03 March 2017
  1. Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012; 23, 533–44. [CrossRef] [Google Scholar]
  2. Held PJ, Port FK, Turenne MN, Gaylin DS, Hamburger RJ, Wolfe RA. Continuous ambulatory peritoneal dialysis and hemodialysis. comparison of patient mortality with adjustment for comorbid conditions. Kidney Int. 1994; 45, 1163–9. [CrossRef] [PubMed] [Google Scholar]
  3. Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Quality of life in patients treated with hemodialysis or peritoneal dialysis. what are the important determinants?. Clin Nephrol. 2003; 60, 341–51. [CrossRef] [PubMed] [Google Scholar]
  4. Mehrotra R M, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011; 171, 110–8. [CrossRef] [PubMed] [Google Scholar]
  5. Yu X, Yang X. Peritoneal Dialysis in China. Meeting the Challenge of Chronic Kidney Failure. Am J Kidney Dis. 2015; 65, 147–51. [CrossRef] [PubMed] [Google Scholar]
  6. Heaf JG, Løkkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. NDT 2002; 17, 112–7. [Google Scholar]
  7. Murphy SW, Foley RN, Barrett BJ, Kent GM, Morgan J, Barré P, et al. Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney Int. 2000; 57, 1720–6. [CrossRef] [PubMed] [Google Scholar]
  8. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int. 2004; 66, 2389–401. [CrossRef] [PubMed] [Google Scholar]
  9. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003; 41, 1212–8. [CrossRef] [PubMed] [Google Scholar]
  10. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Monitoring of inflammation in patients on dialysis. forewarned is forearmed. Nat Rev Nephrol. 2011; 7, 166–76. [CrossRef] [PubMed] [Google Scholar]
  11. Badiou S, Cristol JP, Jaussent I, Terrier N, Morena M, Maurice F, et al. Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination. Clin J Am Soc Nephrol. 2008; 3, 423–30. [CrossRef] [PubMed] [Google Scholar]
  12. Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013; 9, 255–65. [CrossRef] [PubMed] [Google Scholar]
  13. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. NDT. 2001; 16, 36–40. [Google Scholar]
  14. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998; 32, 107–14. [CrossRef] [PubMed] [Google Scholar]
  15. Pecoits-Filho R, Bárány P, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. NDT. 2002; 17, 1684–8. [Google Scholar]
  16. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD. do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients?. J Am Soc Nephrol. 2006; 17, S169–S173. [CrossRef] [Google Scholar]
  17. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003; 290, 353–9. [CrossRef] [PubMed] [Google Scholar]
  18. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT, et al. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004; 15, 2916–22. [CrossRef] [Google Scholar]
  19. Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE. Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers. NDT. 2009; 24, 3826–33. [Google Scholar]
  20. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG, Ma JZ. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis. 1999; 34, 1065–74. [CrossRef] [PubMed] [Google Scholar]
  21. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001; 38, 85–90. [CrossRef] [PubMed] [Google Scholar]
  22. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE. Association between cholesterol level and mortality in dialysis patients. role of inflammation and malnutrition. JAMA. 2004; 291, 451–9. [CrossRef] [PubMed] [Google Scholar]
  23. Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY. Molecular inflammation. underpinnings of aging and age-related diseases. Ageing Res Rev. 2009; 8, 18–30. [CrossRef] [PubMed] [Google Scholar]
  24. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115, 1111–9. [CrossRef] [PubMed] [Google Scholar]
  25. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35, 469–476. [CrossRef] [PubMed] [Google Scholar]
  26. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007; 72, 202–7. [CrossRef] [PubMed] [Google Scholar]
  27. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. NDT. 2004; 19, 1154–60. [Google Scholar]
  28. Washburn KK, Zappitelli M, Arikan AA, Loftis L, Yalavarthy R, Parikh CR, et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. NDT. 2008; 23, 566–72. [Google Scholar]
  29. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2009; 77, 550–6. [CrossRef] [PubMed] [Google Scholar]
  30. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol. 2004; 15, 2186–94. [CrossRef] [Google Scholar]
  31. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients. a prospective study. J Am Soc Nephrol. 2003; 14, 159–68. [CrossRef] [Google Scholar]
  32. Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients. Association with< i> Chlamydia pneumoniae </i> seropositivity. Am J Kidney Dis. 2002; 39, 274–82. [CrossRef] [PubMed] [Google Scholar]
  33. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD. what is the role of interleukin-6?. Kidney Int. 2002; 61, S103–S108. [CrossRef] [Google Scholar]
  34. Porazko T, Küzniar J, Kusztal M, Küzniar TJ, Weyde W, Kuriata-Kordek M, Klinger M. IL-18 is involved in vascular injury in endstage renal disease patients. NDT. 2009; 24, 589–96. [Google Scholar]
  35. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005; 45, 324–33. [CrossRef] [PubMed] [Google Scholar]
  36. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients. causes and consequences. Am J Kidney Dis. 2003; 42, 864–81. [CrossRef] [PubMed] [Google Scholar]
  37. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, et al. Endothelial dysfunction in chronic renal failure. roles of lipoprotein oxidation and pro-inflammatory cytokines. NDT. 2001; 16, 1189–97. [Google Scholar]
  38. Sharma R, Bolger AP, Li W, Davlouros PA, Volk HD, Poole-Wilson PA, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Card. 2003; 92, 188–93. [CrossRef] [Google Scholar]
  39. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, et al. Inflammatory signals associated with hemodialysis. Kidney Int. 2002; 62, 1408–16. [CrossRef] [PubMed] [Google Scholar]
  40. Liakopoulos OJ, Dörge H, Schmitto JD, Nagorsnik U, Grabe dünkel J, Schoendube FA. Effects of preoperative statin therapy on cytokines after cardiac surgery. Thorac Cardiovasc Surg. 2006; 54, 250–4. [CrossRef] [PubMed] [Google Scholar]
  41. Kohut ML, McCann DA, Russell DW, Konopka DN, Cunnick JE, Franke WD, et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of β-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun. 2006; 20, 201–9. [CrossRef] [PubMed] [Google Scholar]
  42. Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomery HE. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 2002; 87, 252–5. [CrossRef] [PubMed] [Google Scholar]
  43. Trebble T, Arden NK, Stroud MA, Wootton SA, Burdge GC, Miles EA. Inhibition of tumour necrosis factor-a and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr. 2003; 90, 405–12. [CrossRef] [PubMed] [Google Scholar]